Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 15/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20024501 | 0.91 | TERT (0.47) | TERTMCHR1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL19611848 | 0.89 | TERT (0.49) | TERTMCHR1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL19636619 | 0.88 | TERT (0.48) | TERTMCHR1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL22754787 | 0.87 | TERT (0.47) | TERTMCHR1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL25963271 | 0.83 | TERT (0.44) | TERTMCHR1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL16260991 | 0.83 | TERT (0.44) | TERTMCHR1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL14310903 | 0.81 | ACKR3 (0.53) | ALDH1A1SMN1; SMN2KDM4ENFKB1BLM | |
| SCHEMBL25963520 | 0.81 | TERT (0.42) | TERTMCHR1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL2444201 | 0.80 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2KDM4ENFKB1KCNH2 | |
| SCHEMBL29472460 | 0.80 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2KDM4ENFKB1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11747310-B2 | Methods for liquid chromatography calibration for rapid labeled N-glycans | WATERS TECHNOLOGIES CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| US-20180188259-A1 | METHODS FOR THE RAPID PREPARATION OF LABELED GLYCOSYLAMINES AND FOR THE ANALYSIS OF GLYCOSYLATED BIOMOLECULES PRODUCING THE SAME | WATERS TECHNOLOGIES CORPORATION (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180094293-A1 | LABELED GLYCAN AMINO ACID COMPLEXES USEFUL IN LC-MS ANALYSIS AND METHODS OF MAKING THE SAME | WATERS TECHNOLOGIES CORPORATION (US) | 2018-04-05 | — | — | US | disclosed |
| US-20170336368-A1 | METHODS FOR LIQUID CHROMATOGRAPHY CALIBRATION FOR RAPID LABELED N-GLYCANS | WATERS TECHNOLOGIES CORPORATION (US) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170336368-A1 | METHODS FOR LIQUID CHROMATOGRAPHY CALIBRATION FOR RAPID LABELED N-GLYCANS | DDOST, STT3B, CSGALNACT1 | TERT 4240/4885MCHR1 2711/4885ALDH1A1 1045/4885 |
| US-11747310-B2 | Methods for liquid chromatography calibration for rapid labeled N-glycans | DDOST, STT3B, CSGALNACT1 | TERT 4240/4885MCHR1 2711/4885ALDH1A1 1045/4885 |
| US-20180094293-A1 | LABELED GLYCAN AMINO ACID COMPLEXES USEFUL IN LC-MS ANALYSIS AND METHODS OF MAKING THE SAME | DNPEP, ASNS, ANPEP | TERT 4865/4885MCHR1 1609/4885ALDH1A1 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.